Table 1 Surgical and Pathological Outcomes (n = 125)

From: Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)

Characteristic

n (%)

Surgical type

 

Ivor-Lewis

44 (35.2)

Mckeown

81 (64.8)

Surgical technology

 

Thoracotomy

28 (22.4)

VATS

64 (51.2)

RATS

33 (26.4)

Pathological T stage

 

pT0

59 (47.2)

pTis

1 (0.8)

pT1a

14 (11.2)

pT1b

15 (12.0)

pT2

21 (16.8)

pT3

14 (11.2)

pT4a

1 (0.8)

Tumor regression grade

 

1

60 (48.0)

2

34 (27.2)

3

19 (15.2)

4

10 (8.0)

Not reported

2 (1.6)

Pathological N stage

 

pN0

100 (80.0)

pN1

24 (19.2)

pN2

1 (0.8)

Number of LNs dissected

 

Median

18

IQR

15

Number of positive LNs

 

Median

0

Range

0–7

Pathological TNM stage

 

I

92 (73.6)

II

7 (5.6)

IIIA

18 (14.4)

IIIB

6 (4.8)

IVA

2 (1.6)

Major pathological response

 

Yes

98 (78.4)

No

21 (16.8)

Not reported

6 (4.8)

Pathological complete response

 

Yes

54 (43.2)

No

71 (56.8)

  1. IQR interquartile range, LN lymph node, RATS robotic-assisted thoracic surgery, VATS video-assisted thoracic surgery